Myeloma Treatment in Republic of Korea — Costs 2026

Seoul St. Mary hospital, Seoul National University Hospital, and Asan Medical Center lead multiple myeloma care in South Korea. These centers utilize advanced hematopoietic stem cell transplantation and early CAR-T cell therapy. Leading facilities hold JCI accreditation and maintain high hematologic malignancy survival rates.

• Asan Medical Center: Serves over 11,000 outpatients daily. It is the largest multidisciplinary center in Korea.
• Seoul National University: Performs at the highest cancer treatment volume. It is a primary state facility.
• Seoul National University Bundang: Employs the digital BESTcare system. This technology reduces medical errors during treatment.
• Severance Hospital: Operates a specialized oncology center. It manages over 1.6 million outpatients every year.

Bookimed Expert Insight: Data shows a major volume gap between specialized university hospitals and local centers. Patients should focus on the Big Four hospitals in Seoul like Asan Medical Center or Seoul National University Hospital. These centers handle the highest volume of cancer procedures. High patient volume directly correlates with better outcomes in complex stem-cell transplants.

Patient Consensus: Patients emphasize choosing Seoul university hospitals over regional centers for complex blood cancer care. Access to specialized hematology teams and transplant expertise are the most critical factors mentioned.

CAR T-cell therapy is available for multiple myeloma in South Korea at major academic cancer centers. Treatment is primary indicated for relapsed or refractory cases. Most access occurs through approved advanced therapies or ongoing clinical trials like CARTITUDE-5. Facilities typically hold JCI or KOIHA accreditations.

• Targeted antigens: Therapies primarily target BCMA proteins found on myeloma cells.
• Access centers: Treatment is concentrated in large tertiary hospitals like Asan Medical Center.
• Standard protocol: Process includes cell collection, bridging therapy, and intensive toxicity monitoring.
• Infrastructure requirements: Hospitals must have specialized labs for genetic reprogramming of cells.

Bookimed Expert Insight: South Korea is a leader in digitalized medicine. Seoul National University Hospital has been fully digital since 2004. This technical maturity allows clinics to manage the complex data tracking required for individual CAR T-cell batches. High patient volumes at centers like Asan Medical Center, which sees over 11,000 outpatients daily, provide the necessary expertise for handling rare treatment reactions.

Patient Consensus: Patients note that qualifying for treatment takes time and requires pre-screening at a major university hospital. They emphasize the need to stay close to the clinic for several weeks to monitor for specific side effects after the cells are returned.

South Korean hospitals monitor myeloma success using standardized protocols and national data-driven analysis. Facilities like Seoul National University Bundang Hospital employ advanced digital systems to prevent medical errors. Clinicians prioritize rapid adoption of novel therapies and triplet regimens to improve longitudinal survival and risk-stratified care.

• Digital monitoring: Seoul National University Hospital uses complete digitalization to track real-time patient data.
• Response assessment: Specialist teams use PET-CT and bone marrow exams to confirm deep remission.
• Regimen adjustment: Doctors rapidly switch therapies if serial M-protein or light chain markers plateau.
• Integrated coordination: Centers like Asan Medical Center utilize multidisciplinary teams to manage complex cases.

Bookimed Expert Insight: While many countries focus on outpatient care, South Korean centers like Asan Medical Center manage high patient volumes, serving over 2,500 inpatients daily. This scale allows for rapid data collection of real-world evidence. Their digital infrastructure, such as the BESTcare system, ensures that treatment adjustments are documented instantly, which is critical for myeloma patients who require frequent dosing changes.

Patient Consensus: Patients note that Korean doctors focus on aggressive side effect management to keep treatment on schedule. They value regular lab checks that monitor kidney health alongside tumor markers as a sign of comprehensive care.

South Korea provides advanced myeloma treatments including CAR-T cell therapy, quadruplet induction regimens, and novel XPO1 inhibitors like Selinexor. JCI-accredited centers in Seoul utilize autologous stem cell transplants and specialized techniques like double filtration plasmapheresis to manage complex cases and relapsed disease effectively.

• Cellular therapy: CAR-T cell therapy focuses on treating relapsed or refractory cases.
• Advanced diagnostics: Specialists use sentinel lymph node biopsy and blood analysis for staging.
• Apheresis techniques: Clinics perform therapeutic plasma exchange and double filtration plasmapheresis (DFPP).
• Drug regimens: Quadruplet therapies often combine anti-CD38 monoclonal antibodies with standard triplet induction.

Bookimed Expert Insight: Major academic centers like Seoul National University Hospital and Asan Medical Center handle massive patient volumes, often exceeding 180,000 annually. This high intensity translates to deep expertise in managing transplant-eligible patients. When choosing a facility, prioritize centers with KOIHA or JCI accreditation, as these typically offer the most streamlined referral pathways for breakthrough CAR-T treatments.

Patient Consensus: Patients note that arriving at a large academic center early is vital for securing eligibility for clinical trials and newer cell therapies. They emphasize that proper bone protection and kidney monitoring are just as critical as the main treatment regimen.

International patients can obtain remote second opinions from South Korean oncology centers before traveling. Specialists at JCI-accredited facilities evaluate diagnostic images and pathology records through secure portals. This process confirms diagnoses and treatment eligibility. It helps patients determine if traveling to Seoul is necessary.

• Required documentation: Patients must provide bone marrow biopsies, cytogenetics, and light chain assays.
• Clinical evaluation: Hematologists review lab trends and imaging to refine complex treatment plans.
• Digital infrastructure: Hospitals like Seoul National University Hospital utilize fully digital patient data systems.
• Coordination support: Specialized departments manage secure file transfers and translation for international patients.

Bookimed Expert Insight: While many patients target major centers based on ranking, the highest success often correlates with massive patient volume. Asan Medical Center treats over 180,000 patients annually and maintains a 90% success rate for complex procedures. Choosing these high-volume tertiary hospitals ensures that remote opinions come from specialists who handle thousands of myeloma cases every year.

Patient Consensus: Patients note it is important to have complete medical records ready before requesting a review. They emphasize that while remote opinions help with travel decisions, doctors often wait until arrival to finalize plans after re-reading original pathology slides.

South Korea is a premier destination for myeloma treatment. It offers world-leading survival rates and advanced technology. Centres like Seoul National University Hospital have completed 1,800 bone marrow transplants. Major hospitals hold JCI and GHA certifications, providing specialised care for complex blood cancers.

• Specialised infrastructure: Asan Medical Center is Korea's largest multidisciplinary hospital. It performs over 65,000 surgeries annually.
• Clinical excellence: Severance Hospital partners with MD Anderson. This means patients receive treatment protocols aligned with global standards.
• Technology: Centres like Gangnam Severance use tomotherapy and robotic systems. Seoul National University Hospital is fully digital.
• International support: Hospitals provide 24/7 interpreters and personal coordinators. Asan Medical Center offers free airport transfers for patients.

Bookimed Expert Insight: While many countries offer stem cell transplants, South Korea's high-volume centres stand out. They provide a unique safety signal. Seoul National University Hospital has performed over 1,000 liver transplants and 1,800 bone marrow transplants. This massive procedural volume means haematology teams have managed every complication. Australian patients benefit from this deep institutional knowledge. This level of experience is rarely found at lower-volume hospitals.

Patient Consensus: Patients note that South Korean hospitals provide excellent technical care. They suggest bringing full pathology reports and marrow results. They also advise arranging an independent caregiver. Bedside nursing care differs from the Australian system. Patients appreciate access to newer drug therapies like selinexor.

South Korean haematologists primarily use the VRd regimen, combining bortezomib, lenalidomide, and dexamethasone. This triplet therapy serves as the standard induction before autologous stem cell transplantation. Leading Seoul hospitals also use carfilzomib and daratumumab for relapsed cases, following global clinical standards.

• Proteasome inhibitors: Bortezomib remains the primary first-line choice for slowing cancer cell growth.
• Immunomodulatory drugs: Lenalidomide is widely prescribed for both initial induction and long-term maintenance.
• Monoclonal antibodies: Daratumumab is increasingly added to regimens for patients ineligible for transplants.
• Second-line options: Carfilzomib or pomalidomide are used when initial treatments no longer work effectively.

Bookimed Expert Insight: While many centres offer standard triplets, top-tier Seoul facilities like Seoul National University Hospital have completed over 1,800 bone marrow transplants. This high volume is critical because drugs like melphalan are used as conditioning agents during these procedures. Patients should look for hospitals with JCI or KOIHA accreditation. These centres often receive earlier access to newly reimbursed targeted therapies through the National Health Insurance system.

Patient Consensus: Patients often undergo a four-drug induction involving bortezomib and dexamethasone, though some note mild fatigue or neuropathy during the process. Patients treated in South Korea appreciate the streamlined diagnostic phase, which typically includes biochemical blood analysis and bone marrow reviews before starting tablets.

South Korea offers myeloma treatments that include autologous stem cell transplants, CAR-T cell therapy, and dual filtration plasmapheresis. Major Seoul hospitals offer triple or quadruple induction regimens using proteasome inhibitors and monoclonal antibodies. Specialist centres regularly perform haematopoietic stem cell transplants for eligible patients under seventy.

• Stem cell transplants: Major centres like Seoul National University Hospital have performed 1,800+ transplants.
• CAR-T therapy: This immunotherapy is available for relapsed or refractory multiple myeloma cases.
• Filtration: Clinics use double filtration plasmapheresis to manage complex or relapsed disease.
• Induction therapy: Standard protocols include bortezomib and lenalidomide combined with dexamethasone or daratumumab.
• Supportive care: Doctors use bone resorption inhibitors and renal support to manage myeloma complications.

Bookimed Expert Insight: While many centres treat oncology, South Korea's university hospitals specialise by volume and infrastructure. Severance Hospital maintains partnerships with MD Anderson and Johns Hopkins. As a result, its protocols align with those of global leaders. Patients should prioritise hospitals like Asan Medical Center. This centre handles 182,000+ patients each year. High volume often correlates with better management of complex drug combinations.

Patient Consensus: Patients find the care at South Korean university hospitals excellent. They often seek second opinions within the system to explore all drug combinations. Patients report that Korean labs usually require original pathology slides or reports. This is to confirm the diagnosis before starting intensive treatment like stem cell transplants.

South Korean doctors at major hospitals speak English. Many trained internationally and use English medical materials. Large university hospitals in Seoul provide 24/7 interpreter services and personal coordinators. These teams help with complex myeloma treatments like CAR T-cell therapy and bone marrow transplants.

• International departments: Seoul National University Hospital handles 30,000 international patients annually.
• Certified specialists: Haematologists at JCI-accredited Severance Hospital partner with MD Anderson in America.
• Translation services: Gangnam Severance Hospital provides free interpreters for foreign patients.
• Personal support: Asan Medical Center assigns a dedicated coordinator to each international patient.

Bookimed Expert Insight: While doctors have high proficiency, admin staff and nurses often have limited English. Bookimed data shows Soon Chun Hyang University Hospital has supported patients from 100+ countries. Choosing hospitals with Global Healthcare Accreditation (GHA) means the facility meets specific standards for international patient communication.

Patient Consensus: Patients note that major university hospitals are the most foreigner-friendly for cancer care in South Korea. They recommend bringing written medical notes and always booking through official international clinics to bridge language gaps.

Accessing CAR-T therapy in South Korea requires referral to specialised tertiary hospitals. These hospitals must be certified by the Ministry of Food and Drug Safety (MFDS). Patients with relapsed myeloma often access this through clinical trials or approved domestic platforms. Treatment involves a multi-departmental assessment at specialised centres like Samsung Medical Centre.

• Specialised centres: Samsung Medical Centre and Seoul National University Hospital hold mandatory MFDS certification.
• Eligibility focus: Patients must generally fail four prior lines of therapy before qualifying.
• Facilities: Seoul St. Mary's Hospital uses an on-site cell processing unit for therapy.
• Clinical trials: Many myeloma patients access BCMA-targeted CAR-T through active international pharma trials.

Bookimed Expert Insight: South Korea is unique because tertiary hospitals like Seoul St. Mary's operate their own GMP cell processing centres. This infrastructure allows hospitals to participate in more global clinical trials than many regional neighbours. Patients often find shorter wait times for trial enrolment compared to the United States or Europe.

Patient Consensus: Patients note that haematologists and neurologists coordinate closely in South Korea. This provides great reassurance during recovery. They often mention that the staff help navigate complex hospital bureaucracies very efficiently.

Standard myeloma treatment in South Korea involves autologous haematopoietic stem cell transplantation (HSCT). This treatment is for eligible patients. This multi-stage process includes induction therapy, stem cell collection, high-dose chemotherapy, and reinfusion. Major Seoul hospitals typically require a 2–3 week hospital stay. This is for monitoring during the recovery phase.

• Induction therapy: Patients complete 3–4 cycles of drug therapy to achieve remission.
• Stem cell collection: Apheresis machines harvest healthy cells over 1–5 days after mobilisation.
• Conditioning phase: High-dose melphalan chemotherapy destroys remaining cancer cells before the transplant.
• Transplant day: Specialists reinfuse thawed stem cells into the bloodstream via a central line.
• Engraftment monitoring: Patients remain in isolation while new blood cells begin to grow.

Bookimed Expert Insight: South Korea's high-volume centres provide exceptional technical depth for complex blood cancers. Seoul National University Hospital has completed over 1,800 bone marrow transplants. This massive volume allows Korean teams to refine recovery protocols. These include specific cryopreservation techniques. These techniques may contribute to better long-term cell viability compared to smaller clinics.

Patient Consensus: Patients note the infusion is relatively quick. However, the following weeks of isolation and managing mouth sores require significant mental preparation. The process in South Korea is highly organised. Coordinators help international patients navigate the transition from induction to the transplant unit.

South Korean university hospitals provide multidisciplinary side-effect management within JCI-accredited facilities. Expert teams including haematologists and neurologists treat complications like peripheral neuropathy and bone loss. Specialised support includes supportive drug therapies, nursing care, and nutritional guidance. This helps maintain quality of life during intensive treatment.

• Multidisciplinary care: Haematologists and neurologists personalise treatments for nerve pain and bone health.
• Nursing: Specialised nurses provide education and continuous monitoring for treatment-related complications.
• Drug support: Clinics use bisphosphonates for bone strength and medications to manage blood counts.
• Digital monitoring: SNUBH uses the BESTcare digital system to enhance patient safety during monitoring.
• On-site services: Asan Medical Center coordinates care for 182,000+ patients annually with dedicated support staff.

Bookimed Expert Insight: South Korea's high-volume oncology centres offer an experience advantage. Seoul National University Hospital, for instance, has completed 1,800+ bone marrow transplants. Their patient volume means nursing teams have likely managed every specific CAR-T or stem cell side effect.

Patient Consensus: Patients emphasise the value of involving palliative care teams early to manage pain and fatigue. Many recommend proactive hydration and clear communication with infusion nurses. This helps adjust medications like gabapentin or anti-nausea drugs quickly in South Korea.

Four-drug regimens like Daratumumab-VRd are considered highly effective in South Korea. However, they are not yet universal first-line standards. Clinicians prefer these quadruplet therapies for newly diagnosed patients. However, national insurance limitations often restrict routine access compared to triplet alternatives. Specialised oncology centres in Seoul regularly offer these protocols.

• Clinical practice: Specialists increasingly use quadruplets as induction therapy to achieve deeper patient responses.
• Standard triplets: Regimens like VRd or VTd remain more common due to current reimbursement.
• Specialised techniques: Major centres like Seoul National University Hospital provide CAR-T and bone marrow transplants.
• Expertise volume: Seoul National University Hospital has completed over 1,800 bone marrow transplants to date.

Bookimed Expert Insight: While triplets are standard, South Korea's massive patient volume creates an expertise edge for complex cases. Seoul National University Hospital alone serves 30,000 international patients annually. This high turnover means local haematologists gain more hands-on experience with diverse drug combinations. They often surpass many Australian specialists.

Patient Consensus: Patients note that Daratumumab-VRd is becoming the global standard. However, insurance coverage depends heavily on the specific hospital's policy in Korea. Those undergoing treatment emphasise preparing for steroid-related side effects. These include sleep disruption and fatigue during intensive induction phases.

International patients can access multiple myeloma clinical trials in South Korea. The country ranks 4th globally for clinical research. It hosts Phase II and III multinational trials. Access depends on strict eligibility criteria and disease stage. The patient must also be able to remain in Seoul for long-term monitoring.

• Research hubs: Seoul National University Hospital and Severance Hospital maintain research partnerships with MD Anderson.
• Clinical volume: Seoul National University Hospital serves 30,000 international patients from 80 countries each year.
• Advanced treatments: Ongoing research focuses on CAR-T therapies and haematopoietic stem cell transplantation for refractory cases.
• Regulatory standards: Trials follow Good Clinical Practice guidelines and hold international accreditation for patient safety.
• Logistical support: Major centres like Asan Medical Center provide personal coordinators to help manage appointments.

Bookimed Expert Insight: While clinical trials offer novel therapies, standard myeloma treatments in Seoul are exceptionally high-volume. Seoul National University Hospital has performed over 1,800 bone marrow transplants. For Australians, this level of procedural experience often provides a reliable alternative. It is useful if trial eligibility criteria cannot be met.

Patient Consensus: Patients note that being a foreigner does not automatically disqualify them from South Korean trials. They emphasise checking if visits must be in-country. They also advise confirming visa arrangements early with the hospital's international desk.